The Innovative Medicines Initiative has launched IMI2 – Call 23.
IMI2 – Call 23 is a standard, two-stage Call for proposals with the following topics:
- Returning clinical trial data to study participants within a GDPR compliant and approved framework
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance (part of IMI’s Antimicrobial Resistance Accelerator programme).
- A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Behavioural model of factors affecting patient adherence
For both the Calls the submission deadline for proposal is 29 September 2020. Short proposals must be submitted via the electronic submission system of the Funding and Tenders Portal. All documents relating to the Call can be found via the Funding and Tenders Portal and the IMI2 Call documents page, in particular the IMI Manual for evaluation, submission and grant award – version 1.7.